FOXO4-D-Retro-Inverso
Senolytic Peptide | p53-FOXO4 Disruptor
DoseGear research brief
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.
FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death). Critically, this mechanism is highly selective: the FOXO4-p53 interaction is a specific vulnerability of senescent cells, while FOXO4 is minimally expressed in healthy tissues, leaving functional cells largely unharmed.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
D-retro-inverso peptide designed around the FOXO4–p53 interaction.
Experimental senescent-cell elimination by disrupting FOXO4–p53 binding in susceptible cells.
A cited mouse experiment used three injections on alternate days; this is an exposure schedule, not a human response estimate.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Standard senolytic protocol | 25-33 mg | 3 doses, every other day (6 days total) | SubQ or IV |
| Mouse study equivalent | 5 mg/kg (translates to ~25 mg for 60kg human) | 3 doses on alternate days | IP (original study) |
Reference cycle
6 days (3 doses total = 75-100 mg per treatment cycle)
Reference storage
Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use immediately or within short term; avoid freeze-thaw cycles
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis
An Example of Senolytic Self-Experimentation with FOXO4-DRI
FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency
FOXO4-DRI Removes Senescent Cells from Human Chondrocytes
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
